T Sonia Boender1, Kim C E Sigaloff2, James H McMahon3, Sasisopin Kiertiburanakul4, Michael R Jordan5, Jhoney Barcarolo6, Nathan Ford6, Tobias F Rinke de Wit1, Silvia Bertagnolio6. 1. Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center of the University of Amsterdam. 2. Amsterdam Institute for Global Health and Development and Department of Global Health, Academic Medical Center of the University of Amsterdam Department of Infectious Diseases, Division of Internal Medicine, Academic Medical Center, University of Amsterdam, The Netherlands. 3. Department of Infectious Diseases, Alfred Hospital, Melbourne, Australia Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts. 4. Division of Infectious Diseases, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Thailand. 5. Tufts University School of Medicine and Tufts Medical Center, Boston, Massachusetts. 6. World Health Organization, Geneva, Switzerland.
Abstract
BACKGROUND: More than 11.7 million people are currently receiving antiretroviral therapy (ART) in low- and middle-income countries (LMICs), and focused efforts are needed to ensure high levels of adherence and to minimize treatment failure. Recently, international targets have emphasized the importance of long-term virological suppression as a key measure of program performance. METHODS: We systematically reviewed publications and conference abstracts published between January 2006 and May 2013 that reported virological outcomes among human immunodeficiency virus type 1 (HIV-1)-infected adults receiving first-line ART for up to 5 years in LMICs. Summary estimates of virological suppression after 6, 12, 24, 36, 48, and 60 months of ART were analyzed using random-effects meta-analysis. Intention-to-treat (ITT) analysis assumed all participants who were lost to follow-up, died, or stopped ART as having virological failure. RESULTS: Summary estimates of virological suppression remained >80% for up to 60 months of ART for all 184 included cohorts. ITT analysis yielded 74.7% (95% confidence interval [CI], 72.2-77.2) suppression after 6 months and 61.8% (95% CI, 44.0-79.7) suppression after 48 months on ART. Switches to second-line ART were reported scarcely. CONCLUSIONS: Among individuals retained on ART, virological suppression rates during the first 5 years of ART were high (>80%) and stable. Suppression rates in ITT analysis declined during 4 years.
BACKGROUND: More than 11.7 million people are currently receiving antiretroviral therapy (ART) in low- and middle-income countries (LMICs), and focused efforts are needed to ensure high levels of adherence and to minimize treatment failure. Recently, international targets have emphasized the importance of long-term virological suppression as a key measure of program performance. METHODS: We systematically reviewed publications and conference abstracts published between January 2006 and May 2013 that reported virological outcomes among human immunodeficiency virus type 1 (HIV-1)-infected adults receiving first-line ART for up to 5 years in LMICs. Summary estimates of virological suppression after 6, 12, 24, 36, 48, and 60 months of ART were analyzed using random-effects meta-analysis. Intention-to-treat (ITT) analysis assumed all participants who were lost to follow-up, died, or stopped ART as having virological failure. RESULTS: Summary estimates of virological suppression remained >80% for up to 60 months of ART for all 184 included cohorts. ITT analysis yielded 74.7% (95% confidence interval [CI], 72.2-77.2) suppression after 6 months and 61.8% (95% CI, 44.0-79.7) suppression after 48 months on ART. Switches to second-line ART were reported scarcely. CONCLUSIONS: Among individuals retained on ART, virological suppression rates during the first 5 years of ART were high (>80%) and stable. Suppression rates in ITT analysis declined during 4 years.
Authors: Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke Journal: Rev Esp Salud Publica Date: 2008 May-Jun
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Bohdan Nosyk; Julio S G Montaner; Guillaume Colley; Viviane D Lima; Keith Chan; Katherine Heath; Benita Yip; Hasina Samji; Mark Gilbert; Rolando Barrios; Réka Gustafson; Robert S Hogg Journal: Lancet Infect Dis Date: 2013-09-27 Impact factor: 25.071
Authors: Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher Journal: PLoS Med Date: 2009-07-21 Impact factor: 11.069
Authors: Raph L Hamers; Rebecca Oyomopito; Cissy Kityo; Praphan Phanuphak; Margaret Siwale; Somnuek Sungkanuparph; Francesca Conradie; Nagalingeswaran Kumarasamy; Mariette E Botes; Thira Sirisanthana; Saade Abdallah; Patrick C K Li; Nicoletta Ngorima; Pacharee Kantipong; Akin Osibogun; Christopher K C Lee; Wendy S Stevens; Adeeba Kamarulzaman; Inge Derdelinckx; Yi-Ming Arthur Chen; Rob Schuurman; Michèle van Vugt; Tobias F Rinke de Wit Journal: Int J Epidemiol Date: 2010-11-10 Impact factor: 7.196
Authors: Ravindra K Gupta; Ruth L Goodall; Michael Ranopa; Cissy Kityo; Paula Munderi; Fred Lyagoba; Lincoln Mugarura; Charles F Gilks; Pontiano Kaleebu; Deenan Pillay Journal: Clin Infect Dis Date: 2013-12-18 Impact factor: 9.079
Authors: Daniel Keebler; Paul Revill; Scott Braithwaite; Andrew Phillips; Nello Blaser; Annick Borquez; Valentina Cambiano; Andrea Ciaranello; Janne Estill; Richard Gray; Andrew Hill; Olivia Keiser; Jason Kessler; Nicolas A Menzies; Kimberly A Nucifora; Luisa Salazar Vizcaya; Simon Walker; Alex Welte; Philippa Easterbrook; Meg Doherty; Gottfried Hirnschall; Timothy B Hallett Journal: Lancet Glob Health Date: 2013-12-10 Impact factor: 26.763
Authors: Uzaib Saya; Sarah MacCarthy; Barbara Mukasa; Peter Wabukala; Lillian Lunkuse; Zachary Wagner; Sebastian Linnemayr Journal: BMC Public Health Date: 2022-05-27 Impact factor: 4.135
Authors: Sarah MacCarthy; Alexandra Mendoza-Graf; Larissa Jennings Mayo-Wilson; Zachary Wagner; Uzaib Saya; Harriet Chemusto; Barbara Mukasa; Sebastian Linnemayr Journal: AIDS Care Date: 2021-11-21
Authors: Fred Kyeyune; Richard M Gibson; Immaculate Nankya; Colin Venner; Samar Metha; Juliet Akao; Emmanuel Ndashimye; Cissy M Kityo; Robert A Salata; Peter Mugyenyi; Eric J Arts; Miguel E Quiñones-Mateu Journal: Antimicrob Agents Chemother Date: 2016-05-23 Impact factor: 5.191
Authors: Robert Gross; Justin Ritz; Michael D Hughes; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Catherine Godfrey; Carole L Wallis; John W Mellors; Victor O Mudhune; Sharlaa Badal-Faesen; Beatriz Grinsztejn; Ann C Collier Journal: Lancet Digit Health Date: 2019-05-06
Authors: Lyolya Hovhannisyan; Lara E Coelho; Luciane Velasque; Raquel B De Boni; Jesse Clark; Sandra W Cardoso; Jordan Lake; Valdilea G Veloso; Beatriz Grinsztejn; Paula M Luz Journal: AIDS Behav Date: 2021-09-25